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Abstract
Antiphospholipid syndrome (APS) is a systemic autoimmune disease 
characterized by thrombosis, obstetric complications and the presence of 
antiphospholipid antibodies (aPL) that cause endothelial injury and thrombophilia. 
Extracellular vesicles are involved in endothelial and thrombotic pathologies and 
may therefore have an influence on the prothrombotic status of APS patients. 
Intercellular communication and connectivity are important mechanisms of 
interaction between healthy and pathologically altered cells. Despite well-
characterized in vitro and in vivo models of APS pathology, the field of extracellular 
vesicles is still largely unexplored and could therefore provide an insight into 
the APS mechanism and possibly serve as a biomarker to identify patients at 
increased risk. The analysis of EVs poses a challenge due to the lack of standardized 
technology for their isolation and characterization. Recent findings in the field 
of EVs offer promising aspects that may explain their role in the pathogenesis of 
various diseases, including APS.
Keywords: Extracellular vesicles, Antiphospholipid syndrome, Antiphospholipid 
antibodies, Thrombosis, Extracellular vesicles, Endothelial cells, Monocytes, Platelets
1. Introduction
Antiphospholipid syndrome (APS) is a systemic autoimmune disease 
characterized by thrombosis and/or obstetric complications and persistent 
presence of antiphospholipid antibodies (aPL) [1]. aPL cause the activation of 
cells involved in the vasculature (endothelial cells, platelets, monocytes) and 
the release of extracellular vesicles (EVs). EVs are submicron particles that are 
constitutively released from nearly all cell types [2] and circulate in plasma of 
healthy individuals in concentrations of approximately 1010 EVs/ml [3]. In response 
to stimuli, such as cell activation due to inflammation and/or apoptosis, increased 
amounts of EVs are released. The frequencies of plasma EVs, which originate from 
different cellular origins, can be altered in disease states [4]. Over the last decade, 
the number of scientific publications describing physiological and pathological 
functions of EVs has increased significantly. The term”extracellular vesicles” is a 
collective term that encompasses various subtypes of cell-releasing membranous 
structures called exosomes, microvesicles, microparticles, ectosomes, oncosomes, 
apoptotic bodies, and many others. The International Society for Extracellular 
Vesicles (ISEV) proposed Minimal Information for Studies of Extracellular Vesicles 
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(“MISEV”) guidelines for accurate isolation and characterizations of EVs [5]. 
MISEV2018 proposes the classification of EVs according to their physical properties 
(size and density), biochemical composition (protein marker positivity), cells 
of origin or based on the description of the conditions that induce their release. 
The heterogeneity of EVs research is, apart from nomenclature, also a reflection 
of poorly standardized methods of isolation and downstream analysis. Complex 
biological samples containing non-EV contaminants pose a challenge for both 
the isolation and characterization of EVs. Usually a combination of different 
methods is used to obtain good data quality. The most common EVs are of platelet 
or megakaryocyte origin (> 50%) [6], while about 5-15% of EVs are of endothelial 
origin [7]. An increase in circulating EVs, especially endothelial EVs, is considered 
a hallmark of vascular dysfunction and cardiovascular disease. Increased EVs are 
found particularly in patients with hypertension [8], diabetes [9], acute coronary 
syndromes [10] and cardiovascular disease [11]. EVs, especially medium to large 
endothelial EVs, have been studied in patients with APS, who had significantly 
higher levels of circulating endothelial and platelet EVs compared with healthy 
controls [12]. One study also reported increased levels of small EVs (sEVs), which 
are less than 200 nm in size, in the plasma of patients with APS [13]. In addition, 
they reported on an altered protein profile of sEVs, indicating platelet and 
endothelial activation. These results show that a complex systemic network that 
exists in the form of cell–cell communication via sEVs is altered in APS patients.
2. Extracellular vesicles
Extracellular vesicles are small particles composed of a phospholipid bilayer 
that encloses soluble cytosolic or endosomal material and nuclear components and, 
unlike a cell, are unable to replicate. EVs can be as small as the smallest physically 
possible unilamellar liposome (about 20-30 nm) or as large as 1 μm or more 
[14]. EVs serve as regulators of the transfer of biological information (proteins, 
nucleic acids, lipids and metabolites), which act both locally and remotely [15]. 
EVs are found in a variety of human biofluids including serum, plasma, urine, 
saliva, breast milk, amniotic fluid, ascites fluid, cerebrospinal fluid and even 
bile [16]. Under normal physiological conditions, they are continuously secreted 
into the extracellular environment, however, the amount of EVs is increased by 
activated and apoptotic cells and is associated with different pathologies, including 
thrombosis [7]. EVs are probably the most extensively studied in cancer and were 
also found to play a significant role in cancer-associated thrombosis [17]. Over the 
last decade, EVs have been extensively studied in the field of biomedical research to 
determine their biological role in normal physiology and in disease state as well as 
to exploit potential clinical applications in the diagnosis and prognosis of disease. 
EVs are considered a promising source of biomarkers since they carry different 
biological materials that reflect the status of the cell of origin. Nevertheless, EVs 
have also been considered as a therapeutic agent, as an alternative to their synthetic 
counterparts, such as liposomes [18].
2.1 Classification of EVs
The classification and nomenclature of EVs is complicated and could be 
confusing due to overlapping definitions. The most common classification of EVs 
currently used in the literature is the classification of different EVs into subtypes, 
such as endosomal derived exosomes, membrane derived (microparticles, 
microvesicles or ectosomes) and apoptotic bodies. This classification is based on the 
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assignment of a specific EV to a particular biogenesis pathway, which remains very 
difficult to assess [19]. Unless biogenesis is investigated directly, EVs are classified 
according to their a) physical characteristics such as size: “small EVs” (sEVs; size 
<100 nm or < 200 nm) and “medium/large” (m/lEVs; size >200 nm), and density; 
low, medium, high, with defined range, b) biochemical composition (surface 
expression or by the presence of a specific molecule within EVs), or c) description 
of a specific condition or cell of origin (Figure 1) [19].
2.2 Biological role of EVs
The key biological function of EVs is cell to cell communication and the transfer 
of biological materials that act closely, but also, and more importantly, remotely. 
Cargo within the EVs is protected from degradation in the bloodstream and can 
be successfully transferred to specific cells of interest, affecting several biological 
functions of these cells. EVs can transfer a wide variety of molecules: heat shock 
proteins (HSP-90, HSP-70), interleukins (IL), such as tumor necrosis factor-alpha 
(TNFα), acute phase proteins, such as serum amyloid A [20], enzymes, peptides, 
growth factors [14]. Therefore, EVs have a wide range of biological functions 
including immune response, antigen presentation, and the transfer of RNA, 
including micro RNA (miR) and DNA. Given the fact that EVs migrate through the 
bloodstream they can have pleiotropic effects that are likely to affect every tissue 
in the body [14]. In immunity, they modulate immune cells, cell–cell interactions, 
and transfer of cytokines and chemokines. In the heart and vessels, they stimulate 
Figure 1. 
Classification of EVs. EVs can be classified according to their size (Small <100 nm or < 200 nm, Medium/
large >200 nm), density (Low, Medium, High) with a defined density range, biogenesis pathway (Exosomes; 
endosomal derived, Microvesicles; membrane derived and Apoptotic bodies; released upon cell apoptosis) or 
biochemical composition defining EVs origin, surface proteins or cargo. Created with BioRender.com.
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coagulation and thrombosis, modulate angiogenesis, calcification and vascular 
repair. In the adipose tissue, they modulate angiogenesis, inflammation, cell 
differentiation and secretion of cytokines. In the bone marrow, they are involved 
in cell–cell cooperation, cell proliferation, differentiation and maturation. In the 
central nervous system, they are involved in the integration of neurons and various 
glial cells, modulate angiogenesis, neuronal plasticity and myelination. In the blood, 
they influence activation and aggregation of platelets, are directly involved in 
coagulation, as well as cargo transfer of procoagulant or anticoagulant molecules, 
cytokines and growth factors [14].
2.3 Methods for EVs isolation
Biological fluids containing EVs, which serve as potential minimally invasive 
liquid biopsies, have shifted its proteomic and genomic profiling research towards 
identification of biomarkers for disease diagnosis, prognosis and longitudinal moni-
toring. Studying EVs and their cargo typically requires separation from a biological 
matrix (such as a complex fluid or tissue) to analyze the unique EV components. 
However, isolating EVs from different sources presents certain challenges. For 
example, in serum and plasma the main challenge is to separate EVs from highly 
abundant non-EV proteins, such as albumin and globulins and non-EV lipid par-
ticles, such as lipoproteins and chylomicrons [21]. These co-purified contaminants 
pose a challenge for the isolation, analysis, and application of EVs. Correct inter-
pretation and detailed reporting of the nature of EV samples and sample handling 
including storage, isolation, and analytical procedures for the analysis of EVs is 
required [18]. Many approaches have been used, including differential ultracen-
trifugation, density gradient ultracentrifugation, size exclusion chromatography, 
and affinity/immunoaffinity capture methods. All these approaches have their 
limitations and advantages, which are challenged by both the source and quantity of 
starting material and the downstream application [21]. Serial centrifugation enables 
the separation of EVs from cells, cell debris and larger vesicles such as apoptotic 
bodies. Ultracentrifugation (UC) exploits high centrifugal speed (100.000 x g) 
for a sufficient time to allow EVs to pellet. It separates particles based on their size, 
shape, and flotation density and is less efficient for smaller and less dense particles. 
Repeated centrifugation can reduce the amount of non-EVs particles, but also 
reduces the yield and may damage the EVs [21]. Density centrifugation or density 
ultracentrifugation uses a density gradient medium or cushion of denser solution 
(e.g. sucrose cushion; sUC) [22] to separate particles of a similar density. This 
technique takes advantage of the fact that particles denser than the solvent sedi-
ment in the suspension, while particles less dense float up. This increases the purity 
of samples and reduces the potential of mechanical damage to the vesicles [23]. 
Density gradient ultracentrifugation is successful in separating chylomicrons, very 
low-density, low-density and intermediate density lipoproteins present in plasma. 
However, particles of similar density, such as high-density lipoproteins, are co-iso-
lated with the EVs [21]. Size exclusion chromatography (SEC) is a chromatographic 
method that allows vesicles of a particular size to be separated where EVs retain 
their structure and physiological function [24]. When performing SEC protein 
contaminants and aggregates of similar size, are often still present. In addition, the 
sample has to be further concentrated because of the different pooled fractions, 
decreasing the yield of isolation. Holcar et al. have investigated the purity of the 
samples by comparing sUC and SEC; the two most commonly used methods for the 
isolation of EVs. Transmission electron microscopy (TEM) of EVs isolated with SEC 
showed increased levels of lipoproteins. This was further confirmed by determining 
a significant increase of ApoA1 (found in high-density lipoproteins) and ApoB100 
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(found in very low-density, low-density and intermediate-density lipoproteins) 
[22]. Based on their results, the presence of lipoproteins in SEC isolates could 
have a significant impact on downstream analysis. Polymer-based precipitation 
uses volume-excluding polymers to lower the solubility of EVs and similarly sized 
non-EV particles which are isolated via low speed centrifugation. The main problem 
using this method is that protein removal kits must be used [21]. The highest purity 
of isolated EVs is achieved by using different immunopurification methods, such as 
immunomagnetic isolation. This method separates EVs on the basis of an antigen–
antibody interactions where the antibodies linked to the matrix (e.g. magnets) are 
directed against a specific antigen of interest on EVs [25]. Using this methodology, 
a specific EV subpopulation is investigated, however, the information about the 
general vesicle population is lost. In addition, when using the immunopurification 
method, EVs stay bound to the matrix, which makes them incompatible with certain 
downstream analyses (Table 1).
2.4 Methods for EVs analysis
The analysis of EVs is greatly hampered by their heterogeneity (size, different 
populations etc.) and by the complex nature of any biological or clinical sample (the 
presence of non-EVs contaminants). The characteristics of EVs can be determined by 
biochemical analysis (immunoblotting, immunosorbent EV assays and flow cytom-
etry) or with physical analysis (electron microscopy (EM), atomic force microscopy 
(AFM), dynamic light scattering (DLS), nanoparticle tracking analysis (NTA), 
tunable restrictive pulse sensing (tRPS) and flow cytometry) as well as novel, opti-
cal based, technologies (fluorescence-based techniques, surface plasmon resonance, 
interferometric imaging and electrochemical sensing) [18] (Table 1). Due to chal-
lenges in EVs analysis, a combination of different methods is very common.
2.4.1 Physical analysis
The physical analyses of EVs involve determining a size range, shape and con-
centration. The size of EVs can be determined directly by high-resolution imaging, 
or indirectly, by using optical or electrical readouts. Direct high-resolution imaging 
includes microscopy methods, such as EM or AFM, to obtain an accurate estimate 
of individual EVs in nanoscale resolution [18]. EM is used to determine the size 
and morphology of individual EVs. This method employs an electron beam instead 
of light to obtain high-resolution images in nanoscale. The most commonly used 
EM techniques are scanning (SEM) and transmission (TEM). Scanning electron 
microscopy image will explore the topography of the EVs surface. Since electrons 
pass through the sample in TEM, a 2D image of EVs will be obtained, which will 
Type of EVs Isolation of EVs Characterization of EVs
Small Ultracentrifugation +/− density gradient, SEC, 
polymer-based approaches, immunopurification
AFM, EM, ELISA, NTA, 
RPS, DLS, WB
Medium/Large Centrifugation +/− density gradient AFM, EM, NTA, IF, ELISA, 
flow cytometry
Abbreviations: AFM: atomic-force microscopy; DLS: dynamic light scattering; ELISA: enzyme-linked 
immunosorbent assay; EM: electron microscopy; IF: immunofluorescence microscopy; NTA: nanoparticle tracking 
analysis; RPS; restrictive pulse sensing; SEC: size exclusion chromatography: EM: transmission electron microscopy 
WB: western blotting.
Table 1. 
Most commonly used methods for isolation and characterization of EVs.
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also provide the information on the inner structure [26]. These electron microscopy 
methods require fixation or drying of the sample which complicates the transla-
tion of observed structures to the native morphology of the EVs. To avoid sample 
dehydration variations of electron microscopy techniques, such as cryogenic TEM, 
have been evolved [27]. In the AFM, an extremely sharp tip scans the area and its 
deflection is translated into topology information. It provides additional information 
about mechanical properties, such as stiffness and elasticity of the vesicles. In most 
cases, AFM is performed on dry, immobilized surfaces, which in turn may damage 
the EVs [28]. This can be prevented by analyzing EVs in a solution [29]. Indirect 
methods estimate the size and concentration based on the interaction of EVs with 
light (DLS and flow cytometry), their diffusion trajectories (NTA or their effect 
on the electrical current (tRPS). DLS is based on the analysis of temporal intensity 
fluctuation of laser light scattered by a dispersion of freely diffusing EVs. Unlike EM 
and AFM it measures the collective mobility (diffusion coefficient) of scattering EVs 
that are present in the measured volume. Flow cytometry is often used to analyze 
the number of cells and their biochemical composition. EVs are much smaller than 
cells and are usually not detected due to the low sensitivity of the method. However, 
adapted protocols have been developed to enable the analysis of EVs [30]. In flow 
cytometry, the flow of cells is hydrodynamically focused in a flow chamber and 
enables the illumination of a single cell by several different lasers. The forward light 
scatter on the cell will allow information on the cells’ sizes while the side scatter will 
gave information on the granularity and composition [31]. Because the EVs are very 
small and have a low refractive index, flow cytometers can more accurately deter-
mine the EVs larger than 500 nm. Smaller EVs are detected in the background signal 
and collectively due to the swarm effect, which happens when multiple EVs are 
simultaneously and not separately illuminated by the laser, creating a swarm [32]. 
The recent advances in the field of flow cytometry enable to detect also populations 
as small as 100 nm [33]. NTA measures how fast a particle diffuses in a static solution 
due to the principle of Brownian particle motion. By analyzing its motion trajecto-
ries, it determines the size distribution of vesicles. tRPS is a technique that measures 
changes in electrical current as each particle passes through an adjustable nanopore 
[18]. The heterogeneity of the samples is a major problem with all indirect methods. 
Compared to direct methods the number of EVs that can be analyzed is typically 
higher, which allows a better estimate of the concentration. This is also due to the 
fact that these vesicles are in their original state. However, these methods are not able 
to provide information on the presence of contaminants, such as lipoproteins.
2.4.2 Biochemical analysis
The characterization of EVs to determine the surface markers, markers of 
origin and proteins they carry allows to infer the functional role of these vesicles 
in health and disease. Methods might be divided to more conventional ones; the 
immunoblotting assays or the methods that will employ the capture of the vesicle; 
immunosorbent methods. Immunoblotting methods are based on the lysis of a 
vesicle and the analysis of its contents either by direct spotting on a membrane (dot 
blot) or separation of proteins using SDS PAGE combined with western blotting, 
in which specific proteins of interest are determined with labeled antibodies. 
Immunoblotting methods are often used to determine the presence of EVs in a 
sample. These methods can also be used to determine the purity of samples [18]. 
Immunosorbent assays are based on the detection of EVs using specific antibodies 
directed against surface proteins of EVs. Derived from the classical enzyme linked 
immunosorbent protein assay (ELISA), EVs are captured on a solid surface coated 
with antibodies that are typically present on the EVs. EVs capture results in a 
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strong enrichment. Analysis of EVs surface proteins is afterwards performed with 
antibodies directed to a protein of interest on the surface of the EVs. These detection 
antibodies are conjugated to an enzyme enabling the conversion of a fluorescent/
colored substrate that can be quantified with a spectrophotometer [18].
3. Extracellular vesicles in vascular pathologies
The main cell types involved in vascular hemostasis are endothelial cells, plate-
lets and monocytes. All these cells release EVs, which leads to a complex interplay 
between different vesicles and different cells. EVs are continuously released in low 
concentrations from the cells into the intercellular environment, but this is greatly 
increased during cellular activation and apoptosis. EVs transmit various biological 
information (in the form of proteins, lipids and nucleic acids). Travelling through 
the bloodstream, EVs serve as local or distant messengers that transmit information 
to a variety of cells and tissues. Hemostasis is a very strictly regulated process that 
maintains normal function of vasculature despite the presence of triggers, such as 
injury and/or infection. One of the consequences of an altered hemostatic balance 
is the formation of thrombi, a process in which EVs play an important role [15]. 
EVs coming from activated cells have been shown to have both procoagulant and 
proinflammatory effects. Procoagulant effects are related to the fact that some EVs 
contain anionic phospholipids, mainly phosphatidylserine (PS), on their surface, 
which contributes to the assembly and activation of the prothrombinase complexes, 
thus promoting thrombin formation [34]. However, not all EVs carry PS on their 
surface, suggesting the involvement of other mechanisms contributing to the pro-
coagulant state [35], including other important coagulation factors, such as tissue 
factor (TF), Factor XII [36], and reduced activity of tissue factor pathway inhibitor 
(TFPI) and thrombomodulin on endothelial cells [37]. In addition, EVs also induce 
the expression of adhesion molecules; integrins and selectins on the recipient cells 
causing platelets, monocytes, and endothelial cells to interact more intensively with 
each another. Finally, EVs also contribute significantly to the proinflammatory state 
in the vascular microenvironment by delivering or inducing certain cytokines and 
chemokines and by transferring nucleic acids and lipids [38]. The effects that these 
EVs have on different cell types disrupt the normal functioning of the vascular 
system, leading to the development of different pathologies, including deep vein 
thrombosis or pulmonary embolism [7] and cardiovascular diseases (atherosclerosis 
[39], hypertension [8], myocardial infarction [40] and stroke [41]).
3.1 Platelet-derived EVs
EVs from activated platelets can have different effects on endothelial cells, 
monocytes and other platelets (Figure 2A). Namely, increased levels of intracel-
lular adhesion molecule-1 (ICAM-1), a well-known activator of endothelium was 
observed on endothelial cells upon stimulation with platelet EVs [42, 43], an effect 
later ascribed to miR-320b transfer [42]. Increased expression of lymphocyte 
function-associated antigen-1 LFA-1 (CD11a/CD18) and macrophage antigen-1 
Mac-1 (CD11b/CD18); both important in mediating monocyte-endothelium inter-
actions, were observed on monocytes upon stimulation with platelet EVs. These 
effects are induced by the transfer of arachidonic acid from platelet EVs and appear 
to be dependent on the activation of protein kinase C [44]. Platelet EVs therefore 
significantly modulate adhesion of monocytes to endothelial cells. It has also been 
shown that platelet EVs increase the deposition of platelets on damaged arteries 
and increase platelet aggregation and adhesion to collagen [45]. By influencing 
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cell adhesiveness, EVs also modulate interactions between leukocytes. Platelet EVs 
use P-selectin to bridge leukocytes, increase leukocyte-leukocyte interactions and 
enhance leukocyte accumulation on a P-selectin surface [46, 47]. Platelet EVs can 
therefore contribute to increased adhesion and aggregation of platelets and leu-
kocytes on blood vessel walls during pathology. In addition, platelet EVs influence 
the production of cytokines (IL-1β, IL-6, IL-8) [43] and the transfer of miRNA 
(miRs 142-3p and 223), affecting the activation, proliferation and apoptosis of 
endothelial cells [48, 49]. In addition, platelet activation by the transfer of arachi-
donic acid from platelet EVs to other platelets, was observed [50]. Importantly, 
the role of platelet EVs in hemostasis is not entirely clear, as there is evidence that 
these EVs can also have anticoagulant effects [51, 52]. Further research is needed 
to determine, which key stimuli are responsible for determining the final effect of 
platelet EVs.
3.2 Endothelial-derived EVs
Endothelial cell activation and damage play an important role in vascular 
pathologies, with endothelial EVs being proposed as one of the causative agents 
in vascular pathologies (Figure 2B). Many proinflammatory factors (e.g. TNF-α, 
lipopolysaccharide, C-reactive protein and reactive oxygen species) and coagula-
tion stimuli (thrombin, plasminogen activator inhibitor-1 (PAI-1)) can increase the 
Figure 2. 
Activation of platelets, monocytes and endothelial cells by EVs deriving from different cells. Schematic 
representation of the potential in vitro mechanisms focusing on vascular function, inflammation and 
thrombosis. (A) Platelet EVs can stimulate endothelial cells and monocytes via direct interaction or cargo 
delivery (miR and lipids). Furthermore, platelets EVs can also act via a feedback loop causing platelet 
aggregation and activation. Platelet EVs induce endothelial cell activation, proliferation and apoptosis by 
the transfer or miR-223 and miR-142-3p while ICAM-1 expression is induced by the delivery of miR-320b. 
Increased adhesion between endothelial cells and monocytes as well as between leukocytes in mediated by 
platelet EVs. (B) EVs released form endothelial cells were found to have a procoagulant profile expressing 
vWF, TF, PAI-1, PS as well as increased adhesive properties expressing VCAM-1, ICAM-1, E-selectin, and 
α-integrin. Endothelial EVs promote procoagulant profile of monocytes by induction of the TF expression on 
these cells. Endothelial EVs induce endothelial dysfunction by attenuating the production of nitric oxide from 
endothelial cells (C) Monocytes release procoagulant EVs that carry TF and PS. Furthermore, monocyte EVs 
interact with endothelial cells causing increased expression of adhesion molecules (ICAM-1, VCAM-1  
and E-selectin), increased inflammation and procoagulant profile by reducing the expression of anticoagulant 
molecules (TFPI and Trombomodulin). Monocyte EVs transfer miR cargo (miR125a-5p, miR-222,  
miR-146a, miR-146b, miR-155) and induce inflammation in endothelial cells. CCL2, C-C motif chemokine 
ligand 2; ICAM-1, intercellular adhesion molecule 1; IL, interleukin; LFA1; lymphocyte function-associated 
antigen 1; Mac-1, Macrophage antigen-1; mIR; micro RNA; MyD88, myeloid differentiation primary response 
gene 88; NO, nitric oxide; PAI-1, plasminogen activator inhibitor-1; PS, phosphatidylserine; TF, tissue factor; 
TLR4, tool like receptor 4; VCAM-1, vascular cell adhesion molecule 1; vWF, von Willebrand factor. Created 
with BioRender.com.
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levels of endothelial EVs. These vesicles carry adhesion molecules; ICAM-1, vascu-
lar cell adhesion protein 1 (VCAM-1), E-selectin, VE-cadherin, α-integrin, growth 
factors; endoglin, CD146, vascular endothelial growth factor (VEGF) receptor and 
molecules involved in coagulation, such as von Willebrand factor (vWF), TF, PAI-1 
[53–55]. The expression of anionic phospholipids; such as PS, together with coagu-
lation molecules, contribute to their procoagulant role. In addition, endothelial EVs 
may interact with other cells such as monocytes and induce the expression of TF on 
these cells [56]. Endothelial EVs induce endothelial dysfunction by attenuating the 
production of nitric oxide from endothelial cells [57]. Conversely, endothelial EVs 
may also have anticoagulant and antiinflammatory potential [38]. Although they 
exert different effects that are mostly dependent on the environment they originate 
from, endothelial EVs are generally believed to impair vascular function [58].
3.3 Monocyte-derived EVs
Leukocytes play an important role in the maintenance of vascular homeostasis. 
The activation of monocytes leads to increased release of monocyte EVs, which 
contribute to the disturbance of the hemostatic balance (Figure 2C). Monocyte 
EVs adhere to endothelial cells via LFA-1-ICAM-1 adhesion, as shown by the 
blocking of LFA-1 [37]. Once internalized, EVs were able to induce extracellular 
signal-regulated protein kinase (ERK1/2) and nuclear factor-κB (NF-κB) signaling 
pathways that increase the expression of the adhesion molecules VCAM-1, ICAM-1, 
and E-selectin on endothelial cells [59]. On the other hand, Tang et al. suggested 
that monocyte EVs induce de novo synthesis of ICAM-1, chemokine C-C motif 
ligand 2 (CCL2) and IL-1β in endothelial cells. This occurs via the activation of toll 
like receptor 4 (TLR4)/Myeloid differentiation primary response gene 88 (MyD88)/
NF-κB [60]. An increase in the adhesion profile of endothelial cells makes them 
more susceptible to interactions with platelets and monocytes and increase the 
prothrombotic state of the vasculature. Monocyte EVs trigger immune dysfunction 
related proinflammatory pathways also by the transfer of different miRs to the 
recipient cells. Levels of miR-125a-5p, miR-146a, miR-146b, miR-155 were signifi-
cantly increased and miR-222 levels were decreased in INFα and lipopolysaccharide 
stimulated monocyte EVs compared to unstimulated monocyte EVs. Monocyte EVs 
transfer functional EVs to endothelial cells and activate the TLR4/MyD88/NF-κB 
signaling leading to differential expression of immunomodulatory miR in endothe-
lial cells [61]. Both monocytes and monocyte EVs are positive for TF [37], a primary 
cellular initiator of blood coagulation. In vascular injury, TF forms a complex with 
factor VIIa, which activates the coagulation protease cascade and eventually leads 
to fibrin deposition and platelet activation [62]. In addition, monocyte EVs reduce 
the expression of the anticoagulant TFPI and of thrombomodulin on endothelial 
cells [37].
4. Pathological mechanisms of the Antiphospholipid syndrome
Antiphospholipid syndrome (APS) is a systemic autoimmune disorder char-
acterized by venous and/or arterial thrombosis and pregnancy complications in 
the presence of antiphospholipid antibodies (aPL). aPL are a heterogeneous group 
of autoantibodies, of which anti-cardiolipin (anti-aCL), anti-β2 glycoprotein I 
(anti-β2GPI) and lupus anticoagulant (LA), are in the laboratory criteria for the 
diagnosis of APS [63]. In addition to criteria aPL other, non-criteria aPL, such as 
antibodies against phosphatidylserine/prothrombin complex, were found to play 
an important role in APS [64, 65]. These antibodies are, in some patients, the only 
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elevated aPL. Although aPL are persistent in APS patients, thrombosis occurs only 
occasionally, suggesting the involvement of other triggers that, together with aPL, 
turn the hemostatic balance in favor of thrombosis. In the development of APS, 
a two hit theory has been proposed in which the continuous presence of aPL as 
the first hit and inflammation, trauma, or surgery as a second hit together lead 
to thrombus formation [66, 67]. APS pathogenesis clearly involves both inflam-
matory and coagulation pathways in endothelial cells, monocytes, neutrophils, 
and platelets. Frequently identified prothrombotic mechanism is inhibition of 
the natural anticoagulant pathways [68]. It has been shown that aPL inhibit the 
activation of protein C [69] and its ability to inactivate factors V and VIII [70]. In 
addition, aPL inhibit the activity of TFPI [71] and activation of antithrombin [72]. 
They have also been found to be involved in fibrinolysis by neutralizing the ability 
of anti-β2GPI to stimulate tissue-type plasminogen activator [73]. Furthermore, 
aPL impair the ability of Annexin A5 to form a network on procoagulant anionic 
phospholipids [74]. aPL also directly bind to vascular cells and trigger their activa-
tion, which in response, release prothrombotic molecules and thus contribute 
significantly to the pathogenesis of APS. The activation of endothelial cells leads 
to a disruption of the normally anticoagulant endothelial surface [68]. This is 
achieved by upregulating adhesion molecules (E-selectin, ICAM-1, VCAM-1) [75], 
molecules involved in coagulation (TF) [76] and by the decrease in endothelial 
cell derived nitric oxide [77]. The biochemical pathways are not fully defined, 
but research has suggested several receptor-mediated mechanisms including, 
annexin A2, TLR4/NF-κB, TLR2, TLR7 and low-density lipoprotein receptor-
related protein 8 [68]. In addition to endothelial cells, aPL also act on platelets. 
Increased production of thromboxane B2, increased platelet adhesion to collagen 
type I and III and increased platelet activation have been described [66]. Among 
immune cells, monocytes are the most extensively studied in APS. In APS patients, 
monocytes have been shown to have a proinflammatory and procoagulant phe-
notype that is mediated by upregulation of NF-κB, MEK-1/ERK, and p38 MAP 
kinase pathways [78]. The main player of the procoagulant phenotype is increased 
surface expression, production and activity of TF on monocytes [79]. Stimulation 
of monocytes with aPL influences the release of IL-1β [80] and TNFα [81], prob-
ably by the activation of NLR family pyrin domain containing 3 inflammasome 
[82]. Monocyte-endothelial interactions are increased by upregulation of adhesion 
molecules on both cell types, as well as expression of other molecules, such as 
monocyte chemoattractant protein-1 by the endothelium, which in turn promotes 
the synthesis of TF by monocytes [83].
5.  Extracellular vesicles in antiphospholipid syndrome: literature review 
and discussion
The role of EVs as communicators between different types of cells involved in 
the pathology of APS have been studied in vivo by analyzing the characteristics of 
EVs from plasma of APS patients and in vitro after stimulation of cells with aPL. As 
discussed above, EVs can carry characteristic proteins that determine their origin 
(Figure 3, upper panel) and their prothrombotic profile (e.g. by the presence of 
TF, PS) (Figure 3, lower panel). However, all EVs carry also different receptors, 
adhesion molecules and cargo (nucleic acids, lipids and proteins), which together 
influence the interaction between different cells, as well as information transfer. 
Larger vesicles (microvesicles) usually carry surface TF, PS and annexins while 
smaller EVs (exosomes) carry surface tetraspanins (CD9, CD63, CD81) and flotillin 
and alix, clathrin and TSG101 proteins as their cargo (Figure 3, lower panel).
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5.1 In vivo studies (characterization of EVs from plasma of APS patients)
The role of EVs has been studied in many vascular pathologies, including deep 
vein thrombosis [7] and cardiovascular disease [38], whose common denominator 
is endothelial dysfunction. In addition, platelet EVs have been proposed as a useful 
biomarker for long-term follow-up after myocardial infarction [84], whereas 
increases in the number of endothelial EVs play a role in many inflammatory 
diseases, such as atherosclerosis [39]. Studies investigating EVs in patients with 
APS are limited and heterogeneous (Table 2). To date and to our knowledge, 
there have been 13 studies investigating EVs in thrombotic APS patients. With one 
exception, all of them have focused on medium/large EVs. Furthermore, the results 
of these studies are not completely comparable because the methods for isolating 
Figure 3. 
Characterization of endothelial, monocyte and platelet EVs. Schematic representation of commonly 
expressed surface protein markers of endothelial cells, monocytes and platelets, as well as markers currently 
associated with small and medium/large EVs. Endothelial EVs usually express CD51 (Integrin alpha V) which 
is a part of a complex that binds extracellular matrix proteins, CD144 (Vascular endothelial cadherin), 
an important cell adhesion molecule in the formation of adherent junctions, CD31 (PECAM-1; platelet 
endothelial cell adhesion molecule) mediates leukocyte- and platelet-endothelial cell adhesion, CD105 
(Endoglin) is a type I membrane glycoprotein and a part of transforming growth factor β receptor complex. 
Monocyte EVs commonly express CD14 (Cluster of differentiation 14) a known monocyte marker and CD45 
(PTPRC; protein tyrosine phosphatase receptor type C) that is leukocyte specific cell surface glycoprotein 
involved in various cellular processes. Platelet EVs usually express different glycoproteins (CD42; glycoprotein 
IX, CD41; glycoprotein IIb, CD61; glycoprotein IIIa) that are integrin complex proteins involved in platelet 
aggregation. All EVs carry adhesion molecules, receptors and lipids that are involved in interaction of EVs with 
different cells. Furthermore, they carry proteins, nucleic acids and lipids that can be transferred to a target cell. 
Membrane derived vesicles-microvesicles, are usually larger and express procoagulant molecules, such as TF 
(Tissue factor), annexins and PS (Phosphatidylserine), whereas tetraspanins (CD9, CD63, CD81) and specific 











Reference Patients Controls Isolation protocol Method of 
quantification
Type of EVs Main findings
Combes et al., 
1999 [53]
5 APS, 8 
APS + SLE






2 x 1,500 × g (15″)
13,000 × g (1″)
AnxV+ or CD51+
< 1.5 μm (latex beads)
endothelial (CD51+) ↑ endothelial EVs in aPL+ pts. vs. HBDs.
↑ endothelial EVs in thrombotic aPL+ pts. vs. 
asympt. aPL+ pts.
Levels of SLE aPL- pts. were similar to HBDs.










platelet (GPIIb-IIIa+) No difference in platelet EVs between APS pts., 






30 HBDs 200 x g (10″, RT),






↑ monocyte EVs in APS pts. vs. APS + SLE pts. and 
vs. HBDs.
↑ P-selectin+ platelets and platelet EVs in APS pts. 
vs. HBDs.
Dignat-




28 SLE aPL+ no 
thrombosis
23 SLE aPL- no 
thrombosis
25 aPL- with 
thrombosis
25 HBDs
2 x 1,500 × g (15″)
13,000 × g (2″)
CD51+
< 0.8 μm (latex beads)
endothelial
(CD51+)
↑ endothelial EVs in APS pts. vs. HBDs and vs. non 
aPL related thrombotic pts.
↑ endothelial EVs in SLE aPL+ pts. vs. HBDs.
No difference between SLE aPL- pts. and non aPL 
related thrombotic pts. vs. HBDs.
↑ endothelial EVs in aPL+ pts. vs. aPL- pts. and vs. 
HBDs.
No difference between primary or secondary APS.
Jy et al., 2007 
[88]










↑ platelet and endothelial EVs in APS pts. vs. 
HBDs.
↑ endothelial EVs in asympt. aPL+ pts. vs. HBDs.
No difference in levels of endothelial EVs in APS 
pts. vs. asympt. aPL+ pts.
↑ platelet EVs in APS pts. vs. asympt. aPL+ pts.
No difference in levels of platelet EVs in asympt. 












Reference Patients Controls Isolation protocol Method of 
quantification




11 APS 9 DVT pts. at 
diagnosis






3000 x g (20″)












No difference in total EVs in DVT pts. at diagnosis, 
FVL pts., APS pts. and HBDs.
↑ total EVs in DVT 1-3 years and HBDs.
No difference in platelet, erythrocyte, monocyte, 




40 APS, 12 
secondary APS
52 HBDs Isolation not 
described
phalloidin-, 
lacadherin+ or CD14+, 
CD42a+, CD142+, 
CD144+









↑ total EVs in APS pts. vs. HBDs.
↑ endothelial, endothelial TF+ and monocyte EVs 
in APS pts. vs. HBDs.






72 asympt. aPL+ 1,500 x g (10″, 
4 °C)
2,000 x g (5″, 4°C)
20,000 x g (30″, 
4°C)
not studied TF+ EVs by a 
functional assay (TF 
activity)
↑ EV-TF activity in APS pts. vs. asympt. aPL+.
No difference in EV-TF activity in the presence or 
absence of underlying SLE.
No difference between different APS clinical 
complications.




47 aPL+ pts. 
(38 APS, 2 
APS + SLE, 
6 asympt. 
aPL+, 1 aPL+ 
migraine)
144 HBDs 2 x 1,500 × g (15″)
13,000 × g (2″)
AnxV+ or CD14+, 
CD41+, CD105+, 
CD142+, CD144+







↑ total EVs in aPL+ vs. HBDs.
endothelial, platelet, and TF+ EVs in aPL+ vs. 
HBDs.











Reference Patients Controls Isolation protocol Method of 
quantification
Type of EVs Main findings
Breen et al., 
2015 [93]






18 HBD 2x 2,000 x g  
(15″, 4°C),








↑ endothelial and platelet EVs in aPL+ pts. vs. 
HBDs.
↑ endothelial and platelet EVs in thrombotic APS 
pts. vs. HBDs.
No difference in levels of endothelial and platelet 
EVs in obstetric APS pts. vs. HBDs.
No difference in levels of endothelial and platelet 
EVs in asympt. aPL+ pts. vs. HBDs.
Niccolai et al., 
2015 [94]
16 APS 16 asympt. aPL+
16 HBDs
1,500 x g (15″)
3,000 x g (3″)
VPD450+ or CD31+, 
CD41a+, CD45+







↑ total, endothelial, platelet, and leukocyte EVs in 
APS pts. vs. HBDs, APS pts. vs. asympt. aPL+ pts. 
and asympt. aPL+ pts. vs. HBDs.
↑ total EVs in APS double and triple positivity vs. 
single positivity.
Different EVs populations (endothelial, platelet 
and monocyte) did not correlate with aPL 
positivity.
↑ endothelial EVs in asympt. aPL+ pts. triple 
positivity vs. single positivity.








30 HBDs 2,500 x g  
(15″, 15 °C)
not studied TF+ EVs by a 
functional assay (TF 
activity)
No difference in EV-TF activity in LA+ pts. with 
thrombosis vs. HBDs.
No difference in EV-TF activity in single, double or 
triple aPL+ patients.
No difference in EV-TF activity in LA+ pts. with AT 
vs. VT vs. combination of both.













Reference Patients Controls Isolation protocol Method of 
quantification
Type of EVs Main findings
Štok et al., 
2020 [13]
14 APS 5 aPL- with 
thrombosis
7 HBD
820 x g (10″, RT)
2,500 x g (10″, RT)
10,000 x g,  
(45″, RT)
100,000 x g 
(2 h15”, 4°C)
NTA < 200 nm. Multiplex 
flow cytometry 
for 38 markers 
(detection via 
tetraspanins)
↑ sEVs in APS pts. vs. HBDs.
Platelet (CD41b+, CD42a+), lymphocyte (CD8+), 
leukocyte (CD45+) and endothelial (CD31+) sEVs 
were detected.
↑ P-selectin on sEVs from APS pts. vs. HBDs.
↑ CD133/1 on sEVs from APS pts. vs. aPL- pts. with 
thrombosis.
Abbreviations: Anx V, annexin V; APS, antiphospholipid syndrome; AT, arterial thrombosis; aPL, antiphospholipid antibodies; asympt., asymptomatic; DVT, deep vein thrombosis; EVs, extracellular 
vesicles; FVL, factor V Leiden; HBDs, healthy blood donors; LLD, lupus like disease; NTA; nanoparticle tracking analysis; pts., patients; sEVs, small extracellular vesicles; SLE, systemic lupus erythematosus; 
TF, tissue factor; VT, venous thrombosis; ↑, elevated levels.
Table 2. 
Isolation, quantification and characterization of EVs in plasma of APS patients.
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and characterizing EVs are not standardized, the sample sizes in some studies are 
small and the patient population studied is very heterogeneous (e.g. patients with 
concomitant autoimmune or other disease). Overall, the studies investigated EVs 
from the three major cell types involved in the pathogenesis of APS: endothelium, 
platelets, and monocytes. Studies in the field of cardiovascular diseases and EVs 
have shown that both platelet and endothelial EVs are elevated in patients with 
hypertension, compared to healthy blood donors [8], therefore it is important to 
note that certain proportion of EVs detected in plasma of APS patients might be 
associated with hypertension. Correlations between the levels of EVs and systolic 
and diastolic blood pressure needs to be evaluated when investigating EVs in APS 
patients.
5.1.1 Medium and large extracellular vesicles
5.1.1.1 Endothelial-derived EVs
The endothelium is the major player in APS pathogenesis, so it is not surprising 
that endothelial EVs have been the most extensively studied (Table 2). Combes et al.  
published in 1999 the first study investigating endothelial EVs in APS using flow 
cytometry to detect endothelial marker integrin CD51+ EVs. They showed increased 
levels of endothelial EVs in LA+ patients compared to HBDs [53]. In addition, they 
have also showed a significant increase in endothelial EVs in LA+ patients with a 
history of thrombosis compared to asymptomatic LA+ patients. On the other hand, 
Jy et al. found no difference in endothelial EVs (CD31+/CD42-) between aPL+ 
thrombotic patients and asymptomatic aPL+ group, suggesting that the release of 
EVs might be related to the autoimmune process involving the presence of aPL [88]. 
Dignat-George et al. in 2004, showed increased levels of CD51+ endothelial EVs in 
APS patients and in aPL+ SLE patients compared to HBDs [87]. Increased levels of 
endothelial EVs were observed in aPL+ patients vs. HBDs as well as in aPL+ patients 
vs. aPL- patients. Increased levels of endothelial EVs in the plasma of APS patients 
compared to HBDs were later confirmed also in several other studies [90, 93, 94] 
(Table 2), in which different endothelial surface markers (CD31+, CD51+, CD105+, 
CD144+) were examined. Levels of endothelial EVs were shown to be increased 
in APS patients with exception of one study where the increase was not observed 
[89]. Chaturvedi et al., on the other hand investigated levels of TF+ endothelial EVs, 
and found them to be elevated in aPL+ patients, compared to HBDs [92]. A higher 
TF activity was also observed when comparing APS patients with asymptomatic 
aPL+ patients [91]. Contrarily, Hell et al. could not observe increased TF activity of 
endothelial EVs in APS patients vs. HBDs.
5.1.1.2 Monocyte- and Platelet-derived EVs
Platelet-derived EVs are the most numerous type of vesicles found in the circulation 
of healthy individuals [96], and their levels are further increased in disease [38]. 
They are known to play key roles in coagulation, thrombosis, vascular senescence 
and permeability. It has been suggested that platelet EVs induce vascular dysfunction 
and influence immune modulation, leading to vascular remodeling. Monocytes 
contribute to APS pathogenesis also by being the main source of tissue factor, which is 
one of the key initiators of the coagulation cascade. Similar to platelet EVs, it has been 
suggested that monocyte EVs cooperate in coagulation and vascular inflammation 
[38]. However, in APS, monocyte EVs (Table 2) have been less extensively studied 
compared to endothelial EVs. Joseph et al., showed no difference in plasma levels of 
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CD41+ platelet EVs between APS patients and HBDs [85]. This is consistent with the 
study by Vikenfors et al. (CD42a+) [97] and by Nascimento et al. (CD61+) [89]. On 
the other hand, increased levels of platelet EVs (CD41+, CD41a+, CD42+, CD42a+) 
were found in five other studies [86, 88, 92–94]. Jy et al. have shown an increase in 
platelet EVs in APS patients vs. asymptomatic aPL+ suggesting thrombosis rather 
than aPL may play a role in platelet EVs release [88]. An increase in monocyte EVs in 
APS patients compared to HBDs was observed by Nagahama et al. and Vikenfors et al. 
which is in contrast to two other studies where the authors could not see an increase 
[89, 92]. There is no consensus on whether platelet and monocyte EVs are elevated in 
APS patients and there is too little data to conclude on the effects of these EVs in APS 
patients.
5.1.2 Small extracellular vesicles
To date, only a study by Stok et al. has investigated the presence of sEVs in 
plasma of APS patients (Table 2). Compared to HBDs, significantly increased levels 
of sEVs were observed in APS patients. In addition, sEVs from different cellular 
origin: platelet (CD41b+, CD42a+), lymphocyte (CD8+), leukocyte (CD45+) and 
endothelial (CD31+) were detected. Flow cytometric characterization of sEVs 
defined a subpopulation of vesicles that were positive for P-selectin (CD62P) and 
the endothelial progenitor cell marker (CD133/1). sEVs from APS patients were 
enriched in surface expression of P-selectin, suggesting endothelial and platelet 
activation in APS. In addition, APS patients showed increased CD133/1 expression 
compared to aPL- patients with thrombosis, suggesting endothelial damage in APS 
[13]. The authors of this study suggest that increased levels of sEVs with distinct 
biological properties circulate in patients with thrombotic APS.
5.2 In vitro studies (characterization of EVs released by aPL stimulated cells)
One mechanism by which aPL promote thromboses is through their binding to 
endothelial cells causing the activation of endothelial cells [98, 99] which in response, 
release EVs that might modulate the activation of other adjacent cells [87, 100]. These 
effects were investigated on endothelial cells [87, 100–102] and placental explants [103] 
involving both small EVs and medium/large EVs (Table 3). A study by Dignat-George 
et al., showed a significant 4-fold increase in endothelial EVs with procoagulant 
activity after stimulation of human umbilical vein endothelial cells (HUVEC) with 
plasma of APS patients [87]. Only a moderate, non-significant increase was observed 
after HUVEC stimulation with the plasma from HBDs. In addition, endothelial 
EVs released after HUVEC stimulation with APS plasma, significantly reduced the 
normalized clotting time ratio. Wu et al. showed data where stimulation of HUVEC 
with anti-β2GPI caused the formation of an endothelial cell inflammasome and the 
release of EVs that were enriched in mature IL-1β, with a distinct mIR profile and 
caused endothelial activation [101]. However, activation of HUVEC does not appear 
to involve IL-1β receptor, but most likely follows the TLR/myd88-IRAK4 signaling 
pathway. Pericleous et al. [102] investigated the effect of purified polyclonal IgG 
from patients with APS (APS-IgG) and healthy controls (HC-IgG) on HUVEC [102]. 
HUVEC exposed to APS-IgG, produced significantly more endothelial EVs than those 
exposed to HC-IgG and a larger proportion of these EVs carried surface E-selectin. 
Levels of ICAM-1+, endoglin+ and VE-cadherin+ EVs did not differ from the ones 
stimulated with HC-IgG. VCAM-1+ and TF+ endothelial EVs could not be detected. 
Later Betapudi et al., also observed a 2-fold increase in levels of endothelial EVs 










Reference Cell type Stimulation Isolation protocol Method of 
quantification of EVs
Levels Other major findings
Dignat-George 
et al., 2004 [87]
HUVEC plasma from APS pts. 
or HBDs
direct use of cell 
culture supernatant
AnxV+ (total EVs)
< 0.8 μm (latex beads)
↑ ↑ endothelial EVs with procoagulant activity.
Wu et al., 2015 
[101]
HUVEC anti-β2GPI purified 
from APS pts. plasma 







NA Anti-β2GPI caused formation of an endothelial 
cell inflammasome and the release of EVs that 
were enriched in mature IL-1β, had a distinct miR 
profile, and caused endothelial activation.
Pericleous et al., 
2013 [102]








CD142+ (TF), CD105+ 
(endoglin), CD144+ 
(VE-cadherin)




No difference in levels of ICAM-1+, endoglin+, and 
VE-cadherin+ EVs after APS IgG stimulation vs. 
HBD IgG. 
VCAM-1+ and TF+ EVs could not be detected.
Betapudi et al., 
2013 [100]
HUVEC anti-β2GPI purified 
from 3 APS pts., HBDs 





< 1 μm (latex beads)
↑ Anti-β2GPI antibodies stimulate endothelial EVs 
release via nonmuscle myosin motor protein-
dependent pathway.

















↑ mean and modal size of EV after aPL 
stimulation.
↑ of mtDNA in EVs after aPL stimulation.
EVs from placental explants activated HMEC-1 
through TLR-9 receptor signaling.
Abbreviations: Anx V, annexin V; APS, antiphospholipid syndrome; aPL, antiphospholipid antibodies; β2GPI, β2-glycoprotein I; EVs, extracellular vesicles; HBDs, healthy blood donors; HUVEC, human 
umbilical vein endothelial cells; HMEC-1, human dermal microvascular endothelial cells; ICAM-1, intercellular adhesion molecule 1; IgG, immunoglobulin G; IL, interleukin; mtDNA, mitochondrial 
DNA; NA, not applicable; NTA, nanoparticle tracking analysis; pts., patients; TF, tissue factor; TLR, toll-like receptor; VCAM-1, vascular cell adhesion molecule 1; ↑, elevated levels.
Table 3. 
Isolation, quantification and characterization of EVs derived from endothelial cells after stimulation with aPL. 
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were studied by Tong et al. [103], whereby exposure of first trimester human placental 
explants to monoclonal anti-β2GPI and IgG fractions from five anti-β2GPI positive 
APS patients did not affect the number or size of EVs. However, an increase in levels 
of mitochondrial DNA was observed in these vesicles that activated endothelial cells 
through a TLR-9-mediated pathway. This is supporting the idea that EV-associated 
mitochondrial DNA could be pathological in pregnant women with aPL.
6. Conclusions
Extracellular vesicles are small phospholipid bilayer particles that carry various 
biologically active molecules, such as proteins, lipids and nucleic acids. Their key 
biological function is cell–cell communication and the transfer of cargo. EVs normally 
circulate in the bloodstream of healthy individuals, but their levels are elevated in 
various pathological conditions, including APS. The classification, isolation and 
characterization of EVs has been developing in an accelerated manner over the last 
20 years. Nevertheless, terms such as exosomes and microparticles are still present in 
the literature, but it is important to note that this classification is based on biogenesis, 
which is rather difficult to assess. It is therefore more optimal to classify EVs based 
on their other characteristics, such as size, density, origin etc. Each isolation and 
characterization techniques have their advantages and disadvantages and influences 
the properties of the EVs studied. Choosing the best combination, albeit of different 
isolation techniques, along with the characterization of EVs, is of utmost importance 
to achieve good data quality. In addition, the limitations of the methods used in both 
isolation and characterization must be considered. In the rapidly developing field 
of EVs research, variations of existing methods, as well as new technologies, are 
emerging that enable more precise isolation and characterization of EVs. EVs from 
platelets, monocytes and endothelial cells play a crucial role in vascular dysfunction, 
which is a causal factor in the disturbance of hemostasis and the development of 
thrombosis. Platelet and monocyte EVs are involved in the increased adhesiveness of 
endothelial cells and the increased interaction of leukocytes with the endothelium. 
Platelet, monocyte and endothelial EVs carry procoagulant molecules, such as TF, 
and modulate the expression of coagulation molecules in endothelial cells. Research 
on EVs in APS is very heterogeneous, due to the lack of standardization of isolation 
and characterization methods, all of which limits solid findings and conclusions. In 
addition to the technological challenges, EVs in APS are difficult to study because of 
the puzzling nature of APS. It is a chronic disease with a complex clinical spectrum 
due to many different features and symptoms (e.g. hypertension, thrombocytopenia). 
Patients with APS receive lifelong treatment with anticoagulants, and the actual acute 
phase is practically impossible to monitor. However, in view of the data on EVs in APS, 
a trend towards elevated total endothelial and platelet EV levels can be observed, sug-
gesting an activated endothelium, even in the absence of an acute event. The results 
of the study of sEVs suggest that smaller vesicle populations may also play a role in the 
pathogenesis of APS. It appears that in patients with APS, levels of sEVs and different 
medium/large EVs are elevated. Further research is needed to confirm this in a larger 
number of patients as well as determine their functionality in APS. Data on increased 
levels of endothelial EVs in APS is supported by in vitro studies showing elevated 
levels of endothelial EVs following stimulation of endothelial cells with aPL. Studies 
investigating the role of aPL in vesicular release and its effects on the original cells also 
suggest that both small and medium/large EVs may play an important role in endothe-
lial dysfunction in APS. However, future studies are needed to obtain a clearer picture 
of the signaling pathways and key molecules involved in interactions of EVs with the 
target cells.
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